orderclomid.info
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes ⋆ Health blog
Abstract Background Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide. Methods We assessed cardiovascular outcomes of once-daily oral semaglutide in an event-driven, randomized, double-blind, placebo-controlled trial involving patients at high …